Bright Minds Biosciences (DRUG) News Today $35.31 -0.80 (-2.22%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$31.28 -4.03 (-11.40%) As of 04/2/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Bright Minds Biosciences Inc. (NASDAQ:DRUG) Short Interest UpdateBright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 107,700 shares, a decline of 14.8% from the February 13th total of 126,400 shares. Approximately 2.2% of the company's stock are sold short. Based on an average trading volume of 79,700 shares, the days-to-cover ratio is currently 1.4 days.March 20, 2025 | marketbeat.comCantor Fitzgerald Has Weak Forecast for DRUG FY2025 EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Bright Minds Biosciences in a research report issued to clients and investors on Thursday, March 13th. Cantor Fitzgerald analyst C. Duncan now expects tMarch 17, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Trading Down 0.8% - Here's WhyBright Minds Biosciences (NASDAQ:DRUG) Shares Down 0.8% - Here's What HappenedMarch 15, 2025 | marketbeat.comBright Minds Biosciences expands Scientific Advisory BoardMarch 4, 2025 | markets.businessinsider.comBright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy ResearchMarch 4, 2025 | markets.businessinsider.comHC Wainwright Issues Pessimistic Estimate for DRUG EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for Bright Minds Biosciences in a research note issued to investors on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now forecastFebruary 22, 2025 | marketbeat.comBright Minds Biosciences' (DRUG) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $85.00 price objective on shares of Bright Minds Biosciences in a research report on Wednesday.February 20, 2025 | marketbeat.comBright Minds Biosciences (DRUG) Receives a New Rating from Piper SandlerFebruary 14, 2025 | markets.businessinsider.comBright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPSBright Minds Biosciences (NASDAQ:DRUG - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.24.February 14, 2025 | marketbeat.comBiotechs on the Brink: 2 Stocks With Huge Potential (DRUG)BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.February 14, 2025 | marketbeat.comBright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101January 26, 2025 | seekingalpha.comPiper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationJanuary 24, 2025 | msn.comBright Minds Biosciences initiated with an Overweight at Piper SandlerJanuary 23, 2025 | markets.businessinsider.comYasmeen Rahimi’s Buy Rating on Bright Minds Biosciences Driven by Promising Potential of BMB-101 for Epilepsy TreatmentJanuary 23, 2025 | markets.businessinsider.comCantor Fitzgerald Forecasts DRUG FY2025 EarningsBright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Bright Minds Biosciences in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the company will poJanuary 23, 2025 | marketbeat.comPiper Sandler sets $93 target for Bright Minds Biosciences stockJanuary 23, 2025 | msn.comBright Minds Biosciences (NASDAQ:DRUG) Earns Overweight Rating from Analysts at Piper SandlerPiper Sandler started coverage on Bright Minds Biosciences in a research report on Thursday. They set an "overweight" rating and a $93.00 price target on the stock.January 23, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight RecommendationJanuary 11, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Bright Minds Biosciences (DRUG) with Buy RecommendationJanuary 11, 2025 | msn.comBright Minds Biosciences initiated with a Buy at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comBright Minds Biosciences initiated with a Buy at H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comBright Minds Biosciences initiated with an Overweight at Cantor FitzgeraldJanuary 10, 2025 | markets.businessinsider.comBright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Cantor FitzgeraldCantor Fitzgerald began coverage on Bright Minds Biosciences in a research note on Friday. They set an "overweight" rating on the stock.January 10, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC WainwrightHC Wainwright assumed coverage on Bright Minds Biosciences in a report on Friday. They set a "buy" rating and a $85.00 target price on the stock.January 10, 2025 | marketbeat.comTop 5 Small-cap Biotech Stocks (Updated January 2025)January 9, 2025 | msn.comTop 5 Small-cap Biotech Stocks of 2025January 8, 2025 | msn.comBright Minds Biosciences Appoints Stephen Collins As CMOJanuary 7, 2025 | markets.businessinsider.comBright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical OfficerJanuary 7, 2025 | globenewswire.comBright Minds Biosciences (NASDAQ:DRUG) Releases Earnings ResultsBright Minds Biosciences (NASDAQ:DRUG - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter.January 1, 2025 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% - Time to Sell?Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Down 4.3% - What's Next?December 19, 2024 | marketbeat.comBright Minds Biosciences (NASDAQ:DRUG) Upgraded by Baird R W to Strong-Buy RatingBaird R W upgraded shares of Bright Minds Biosciences to a "strong-buy" rating in a report on Monday.November 27, 2024 | marketbeat.comBright Minds Biosciences: Promising Pipeline and Strategic Positioning Justify Buy RatingNovember 26, 2024 | markets.businessinsider.comBaird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform RecommendationNovember 26, 2024 | msn.comBright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual MeetingNovember 22, 2024 | finance.yahoo.comBright Minds Biosciences to Present Novel Epilepsy DataNovember 22, 2024 | markets.businessinsider.comBright Minds Biosciences participates in a conference call with TruistNovember 20, 2024 | markets.businessinsider.comBright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementNovember 4, 2024 | globenewswire.comBright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market PotentialOctober 30, 2024 | seekingalpha.comShort Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 1,274.9%Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a significant increase in short interest in October. As of October 15th, there was short interest totalling 1,170,000 shares, an increase of 1,274.9% from the September 30th total of 85,100 shares. Approximately 38.2% of the company's stock are short sold. Based on an average trading volume of 2,890,000 shares, the short-interest ratio is currently 0.4 days.October 25, 2024 | marketbeat.comSteven Cohen's Strategic Acquisition of Bright Minds Biosciences Inc SharesOctober 24, 2024 | uk.finance.yahoo.comCormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences SharesOctober 23, 2024 | finance.yahoo.comBright Minds and Firefly Neuroscience Renew CollaborationOctober 22, 2024 | markets.businessinsider.comBright Minds, Firefly Neuroscience to collaborate after BREAKTHROUGH studyOctober 22, 2024 | markets.businessinsider.comWhat's Going On With Bright Minds Biosciences Stock?October 22, 2024 | msn.comBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataOctober 21, 2024 | globenewswire.comMarketBeat Week in Review – 10/14 - 10/18 (DRUG)Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.October 19, 2024 | marketbeat.comBright Minds rebounds after $35M private placementOctober 18, 2024 | msn.comWhat's Going On With Bright Minds Biosciences Stock Friday?October 18, 2024 | msn.comBright Minds Biosciences Inc. (NASDAQ:DRUG) Major Shareholder Cormorant Asset Management, Lp Acquires 372,591 SharesOctober 18, 2024 | insidertrades.comBright Minds Biosciences Announces US$35 Million Non-Brokered Private PlacementOctober 18, 2024 | globenewswire.com Remove Ads Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address DRUG Media Mentions By Week DRUG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRUG News Sentiment▼0.000.52▲Average Medical News Sentiment DRUG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRUG Articles This Week▼02▲DRUG Articles Average Week Remove Ads Get Bright Minds Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mineralys Therapeutics News Today Spyre Therapeutics News Today Enliven Therapeutics News Today Collegium Pharmaceutical News Today Nurix Therapeutics News Today Vir Biotechnology News Today Phibro Animal Health News Today Xeris Biopharma News Today Oculis News Today Zymeworks News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRUG) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DRUG Stock Free DRUG Stock Alerts